Medytox, Inc. v. ITC — Fed. Cir. (Nov 9, 2026)

Listen through the publisher, then discuss the episode here or arrange an in-person Roundtable. Your city determines where to meet.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
The Federal Circuit hears Medytox's appeal in a dispute over the bacteria used to make botulinum toxin products. Medytox accused a rival manufacturer, Hugel, of wrongfully taking its bacterial culture and sought action against imported products at the United States International Trade Commission. An administrative law judge rejected the claim, and the Commission agreed that Medytox had not proved that its property had been converted. The earlier trade-secret allegations had already been removed from the investigation; the issue now is the alleged wrongful taking of property. Medytox will ask the court to overturn the Commission's finding, while the Commission will defend it. As you listen, keep the burden of proof in view: questioning a rival's story is not the same as proving that it took property that belonged to you. Medytox, Inc. v. ITC (No. 25-1262) — U.S. Court of Appeals for the Federal Circuit, argued November 9, 2026. Sources: Argument audio — official Federal Circuit recording, November 9, 2026; complete source with gentle volume balancing, no noise filtering or speech reconstruction: Commission notice — U.S. International Trade Commission, Investigation No. 337-TA-1313, October 10, 2024: Medytox investigation-institution statement — attributed party account, May 3, 2022: Hugel initial-determination statement — party account, June 10, 2024:
Episode information is provided by the publisher. Listening takes place on the publisher’s service.
Listen at the source ↗







